We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

197 hedge funds and large institutions have $2.58B invested in BridgeBio Pharma in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 58 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more call options, than puts

Call options by funds: $120M | Put options by funds: $93.5M

21% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 58

2% more capital invested

Capital invested by funds: $2.53B → $2.58B (+$43.2M)

1.81% less ownership

Funds ownership: 95.15% → 93.34% (-1.8%)

8% less funds holding

Funds holding: 213 → 197 (-16)

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

34% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 44

Holders
197
Holders Change
-16
Holders Change %
-7.51%
% of All Funds
3.09%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.11%
New
29
Increased
70
Reduced
58
Closed
44
Calls
$120M
Puts
$93.5M
Net Calls
+$26.3M
Net Calls Change
+$24.6M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$29M
2
LCM
Laurion Capital Management
New York
+$18.6M
3
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$16.4M
4
FLSM
Frazier Life Sciences Management
California
+$12.3M
5
Invesco
Invesco
Georgia
+$9.5M

Top Sellers

Rank Fund Capital Flow
1
AIG
American International Group
New York
-$26M
2
Marshall Wace
Marshall Wace
United Kingdom
-$18M
3
APM
Avidity Partners Management
Texas
-$16.6M
4
HA
HHLR Advisors
Cayman Islands
-$14.8M
5
Renaissance Technologies
Renaissance Technologies
New York
-$12.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
PM
226
Prosight Management
Texas
– -$216K -13,000 Closed
ECM
227
ExodusPoint Capital Management
New York
– -$209K -12,624 Closed
Lazard Asset Management
228
Lazard Asset Management
New York
– -$203K -12,292 Closed
CC
229
Centiva Capital
New York
– -$197K -11,900 Closed
BCM
230
Bayesian Capital Management
New York
– -$178K -10,728 Closed
SC
231
Shay Capital
New York
– -$110K -7,300 Closed
QT
232
Quantbot Technologies
New York
– -$46.4K -2,800 Closed
IUHSA
233
Itau Unibanco Holding S.A.
Brazil
– -$35.5K -2,144 Closed
SSG
234
Summit Securities Group
New York
– -$33K -2,000 Closed
CG
235
Cutler Group
California
– -$26.3K -1,746 Closed
SC
236
Slow Capital
California
– -$16.6K -1,000 Closed
TWA
237
TCI Wealth Advisors
Arizona
– -$10.5K -632 Closed
BAM
238
Belpointe Asset Management
Nevada
– -$10.4K -625 Closed
EI
239
Ellevest Inc
New York
– -$9.1K -549 Closed
SC
240
Schubert & Co
Texas
– -$448 -27 Closed
6 7 8 9
10

BBIO Hedge Fund Activity: Q2 2023 in Review

197 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2023, worth a combined $2.58B — up 1.7% from $2.53B a quarter earlier.

Sellers outnumbered buyers: 44 funds closed out of BBIO and 29 opened new positions — a net loss of 15 holders — while 58 trimmed existing stakes and 70 added.

The largest buyer was State Street, adding an estimated $29M. The largest seller was American International Group, cutting an estimated $26M.

  • 197 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2023, down from 213 in Q1 2023.
  • Funds reported $2.58B of BridgeBio Pharma stock for Q2 2023, up 1.7% quarter-over-quarter.
  • 29 funds opened new BridgeBio Pharma positions in Q2 2023 and 44 closed out, a net change of -15 holders.
  • The largest BridgeBio Pharma buyer in Q2 2023 was State Street, an estimated $29M added.
  • The largest BridgeBio Pharma seller in Q2 2023 was American International Group, an estimated $26M sold.

Based on aggregated 13F filings for Q2 2023.